AETHLON MEDICAL INC (AEMD)
US00808Y4061 - Common Stock
Taking everything into account, AEMD scores 3 out of 10 in our fundamental rating. AEMD was compared to 192 industry peers in the Health Care Equipment & Supplies industry. The financial health of AEMD is average, but there are quite some concerns on its profitability. While showing a medium growth rate, AEMD is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
AEMD had negative earnings in the past year.
AEMD had a negative operating cash flow in the past year.
AEMD had negative earnings in each of the past 5 years.
In the past 5 years AEMD always reported negative operating cash flow.
1.2 Ratios
AEMD's Return On Assets of -117.34% is on the low side compared to the rest of the industry. AEMD is outperformed by 84.90% of its industry peers.
AEMD's Return On Equity of -160.89% is on the low side compared to the rest of the industry. AEMD is outperformed by 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.34% | ||
| ROE | -160.89% | ||
| ROIC | N/A |
ROA(3y)-65.45%
ROA(5y)-81.58%
ROE(3y)-74.81%
ROE(5y)-109.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AEMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AEMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
AEMD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AEMD has been increased compared to 5 years ago.
There is no outstanding debt for AEMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AEMD has an Altman-Z score of -22.88. This is a bad value and indicates that AEMD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -22.88, AEMD is not doing good in the industry: 89.58% of the companies in the same industry are doing better.
AEMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.88 |
ROIC/WACCN/A
WACC9.97%
2.3 Liquidity
A Current Ratio of 3.93 indicates that AEMD has no problem at all paying its short term obligations.
AEMD has a Current ratio (3.93) which is in line with its industry peers.
A Quick Ratio of 3.93 indicates that AEMD has no problem at all paying its short term obligations.
AEMD has a better Quick ratio (3.93) than 68.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.93 |
3. Growth
3.1 Past
AEMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.47%, which is quite impressive.
Looking at the last year, AEMD shows a very strong growth in Revenue. The Revenue has grown by 5600.00%.
Measured over the past years, AEMD shows a very strong growth in Revenue. The Revenue has been growing by 30.60% on average per year.
EPS 1Y (TTM)33.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-14.17%
Revenue 1Y (TTM)5600%
Revenue growth 3Y-4.28%
Revenue growth 5Y30.6%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 24.31% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.76%
EPS Next 2Y24.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AEMD. In the last year negative earnings were reported.
Also next year AEMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AEMD's earnings are expected to grow with 24.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.31%
EPS Next 3YN/A
5. Dividend
5.1 Amount
AEMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AETHLON MEDICAL INC
NASDAQ:AEMD (5/3/2024, 7:00:00 PM)
1.39
+0.02 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.64M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.34% | ||
| ROE | -160.89% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)33.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5600%
Revenue growth 3Y-4.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y